Watchlist Price Alert

Atai Life Sciences N.V. (ATAI)

NASDAQ: ATAI · Real-Time Price · USD

2.75

0.04 (1.48%)

At close: Jul 02, 2025, 3:59 PM

2.69

-2.18%

After-hours: Jul 02, 2025, 07:59 PM EDT

1.48% (1D)

Bid	2.69
Market Cap	552.07M
Revenue (ttm)	1.86M
Net Income (ttm)	-148.99M
EPS (ttm)	-0.91
PE Ratio (ttm)	-3.02
Forward PE	-4.48
Analyst	Strong Buy

Ask	2.77
Volume	11,183,078
Avg. Volume (20D)	2,964,842
Open	2.84
Previous Close	2.71
Day's Range	2.66 - 2.96
52-Week Range	1.03 - 2.96
Beta	1.48

About ATAI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ATAI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ATAI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 days ago New

+23.74%

Atai Life Sciences shares are trading higher after... Unlock content with Pro Subscription

1 week ago

+4.46%

Shares of psychedelic companies are trading higher following a report suggesting that the US Department of Health and Human Services Secretary Robert F. Kennedy Jr said the agency is committed to expanding research on the benefits of psychedelic therapy and is working with the FDA head to provide legal access for military veterans within 12 months.

News

1 day ago · proactiveinvestors.com

atai Life Sciences price target boosted on robust BPL-003 mid-stage trial results

The atai Life Sciences (NASDAQ:ATAI, ETR:9VC) story has become more attractive following the release of robust Phase 2b trial results for BPL-003 in treatment-resistant depression, analysts at Jefferi...

1 day ago · seekingalpha.com

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Atai Life Sciences' BPL-003 showed robust, rapid, and durable antidepressant effects in Phase 2b TRD data, spiking shares over 20%. BPL-003's short clinic time and strong efficacy could fit existing t...

22 hours ago · proactiveinvestors.com

Atai and Beckley Psytech hail DMT trial results in treatment-resistant depression

Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline results from its Phase 2b clinical study in patients with treatment-resistant depression, and a private placement for gross proceed...

1 day ago · benzinga.com

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Atai Life Sciences ATAI and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (...

1 week ago · zacks.com

Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?

Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

1 week ago · proactiveinvestors.com

atai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts say

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) remains a ‘Buy' for analysts at Jefferies, who continue to see significant upside ahead for the company following the release of new data from Compass Pathway...

2 weeks ago · proactiveinvestors.com

Psychedelics regain momentum in 2025 on political tailwinds, clinical wins

The psychedelics sector is experiencing a resurgence of optimism in 2025 driven by a more favorable federal government under President Donald Trump's administration, shifting state-level policies, and...

2 weeks ago · proactiveinvestors.com

FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks

The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude toward...